Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.19

-1.4%

Dec 30 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (10772)	3/5/2004 9:23:42 AM
From: software salesperson	Read Replies (1) of 52153

Message 19881530 nbix at lehman 3/4/04 lehman brothers no slides sleep maintenance : for middle of the night awakenings; a unique study; I has advantage due to short ½ life, so can take at 3 am ; no tolerance issues re: efficacy at 4 weeks vis-à-vis 1 week sleep mtn. is one competitive differentiator for I to existing and potential new drugs also, for sleep mtn., 1 hr. improvement(reduction) in WASO is greater than others in development didn’t say what % of patient population had this problem long-term treatment : = removal of short-term restriction( there’s the answer to my question of the other day); now saying that fda guidelines for long-term label require 100 patients to have received 12 months of treatment, rather than previously saying that 2 long-term trials were needed- - hmmmm sales

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next